SciELO - Scientific Electronic Library Online

vol.50 número4Quiste epidermoide supraselar con rotura intraventricular: caso clínicoProtocolo de manejo del intento suicida en el Hospital del Salvador en Santiago de Chile índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados


Revista chilena de neuro-psiquiatría

versión On-line ISSN 0717-9227


SOTO V, Álvaro  y  CARCAMO P, Daniel A. New oral anticoagulants in stroke prevention. Rev. chil. neuro-psiquiatr. [online]. 2012, vol.50, n.4, pp.239-248. ISSN 0717-9227.

Introduction: Atrial fibrillation (AF) is the most common arrhythmia. AF increases stroke risk by 5-fold and accounts for 15% of stroke. For more than 50 years, vitamin K antagonists were the only available oral anticoagulation. The two major classes of novel oral agents are direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (apixaban or rivaroxaban). These new agents require no routine laboratory monitoring and they are administered in a fixed dose. Method: A non systematic literature review was performed. Results: We performed a critical review of articles about new oral anticoagulants in stroke prevention. We evaluated properties of these agents and we compare efficacy and safety outcomes shown in clinical trials about new oral anticoagulants in AF. Discussion: New oral anticoagulants are at least as good as warfarin at preventing stroke in patients with AF. They seem to be safer than warfarin with significantly less intracranial bleeding. Trials demonstrate dabigatran to be the most effective in decreasing ischemic strokes, apixaban superior to warfarin with statistically lower mortality, and rivaroxaban no worse than warfarin for those with higher stroke risk. Conclussion: New oral anticoagulants have several advantages in comparison with warfarin, but we need further trials to know better the efficacy and safety of these new agents.

Palabras clave : Atrial fibrillation; oral anticoagulation; warfarin; dabigatran; apixaban; rivaroxaban.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons